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Firstly it is important to mention that Sudan is split into Sudan and South of Sudan and that this article 
focuses primarily on Sudan. Sudan is a Least Developing Country (LDC) which has not yet had had 
the opportunity of accession to the World Trade Organisation (WTO) and the Trade Related Aspect of 
Intellectual Property Rights (TRIPS) Agreement. Sudan has recently re-opened negotiations into 
acceding into WTO and has been commended, for its efforts to continue negotiations after 13 years of 
‘impasse’.1 Sudan is going through legal changes and gearing up to be a part of the TRIPS family. 
Studies carried out by Oxfam, have raised questions as to whether the protections required under 
TRIPS are appropriate for countries at lower levels of development.  This article recommends steps 
that Sudan can take to improve its access to medicines before acceding into WTO, TRIPS and signing 
Free Trade Agreements (FTA) .   
 
Health and Economic factors affecting Sudan’s access to medicine 
 
It is essential to consider health and economic factors when discussing access to medicine in Least 
Developing Countries (LDCs) because it sheds lights on the capabilities that a country has to 
implement and police change. Barriers for access to medicine, in poorer countries, have been from ‘on 
the ground’ which means that it is not due to inflated patent prices or delayed entry of generics or the 
prohibition of using compulsory licenses in times of emergency, as is the case with developing and 
many developed countries, but issues such as ‘market failure, corruption, non-existent health human 
resources and infrastructure and the lack of both local and international political will’ which were 
present in the last 20 years in LDCs2 and continue to affect access to health.  
HIV/AIDS remains an issue today, for many developing countries and LDCs including Sudan, which 
affects 56,000 adults and children.3 This is not a new issue and has been on the rise since 1990s in 
Sudan.4 Sudan also suffers from Malaria, which is a major public health problem and a deadly 
                                                 
1 WTO, ‘Positive momentum for Sudan’s WTO membership negotiations’ , 14 July 2017, available on 
https://www.wto.org/english/news_e/news17_e/acc_sdn_17jul17_e.htm , last accessed on 27 August 2018 
2 D. W. Taylor, Pharmaceutical Access in Least Developed Countries: on-the-ground barriers and industry 
successes”, Cameron Institute, 2010 available on 
http://apps.who.int/medicinedocs/documents/s17815en/s17815en.pdf  (Hereafter Taylor 2010) Also see P. 
Farmer, AIDS and Accusations: Haiti and the Geography of Blame, Berkeley CA: University of California 
Press, 1990; World Health Organization. The Rational Use of Drugs: Report of a conference of experts, Nairobi, 
25-29 November 1985. 
3 UNAIDS Fact Sheet, Sudan 2016,  http://www.unaids.org/en/regionscountries/countries/sudan  
4 Ibid  
disease5 and has the highest rate of visceral leishmaniasis or ‘kala azar’ ,where Sudan’s Al Gedaref 
accounts for 70% of the world’s patient population. 6 
Over 20% of ‘medicines supplied to government-run facilities in LDCs are stolen and resold by staff 
thus explaining, in part, the chronic stock shortages in public health system dispensaries.’7 Other 
factors that limit the individuals access to medicine are the supply chain mark ups from manufacturers 
which ‘found in private pharmacies and other retailers are typically 300-500% for generics and 1000- 
1500% leading brand name medicines’. 8 Moreover, patients are often ‘ill-advised and inadequately 
supported in medicine purchasing’9 and lack medical human resources10 as Africa for example needs 
800,000 doctors and nurses. 11  
Sudan’s productive capacity is limited and has severe infrastructure deficits.12Sudan struggles with 
improving human development and social development and lacks adequate governance capacities and 
suffers from extreme poverty.13 It is of no surprise, therefore, that ‘the healthcare infrastructure has 
totally collapsed in sub-Saharan Africa.’14  Further issues such as  ‘the stigma of HIV/AIDS, the low 
status of women, and the absence of potable water’ renders access to medication ‘problematic’. 15 
Statements by the International Development Research Centre (IDRC) of CIDA (the Canadian 
International Development Agency) calls into ‘serious question’ the possibility of achieving any 
‘health related goals’ when taking into consideration ‘the disparity between the financial 
commitments that are needed even for a minimal package of essential healthcare interventions and 
current levels of development assistance.’16 
The issues that LDCS have struggled with health and economy have not gone unnoticed. There are 
many forums where LDCs have been recognised as needing particular attention and well targeted 
support measures to eradicate poverty, sustainable development and overcome its vulnerabilities; 
these forums include the ‘United Nations Conferences on the Least Developed Countries’, the 
                                                 
5 Regional Health System Observatory World Health Organization, ‘ Health System Profile: Sudan’ , 2006, 
available on http://apps.who.int/medicinedocs/documents/s17310e/s17310e.pdf  
6 MSF, International Activity Report 2017, Sudan, available on https://www.doctorswithoutborders.org/what-
we-do/countries/sudan , last accessed on 20 December 2018 
7 Taylor 2010 
8 Ibid 
9 Ibid 
10 Ibid  
11 Ibid 
12 UN, ‘Programme of Action for the Least Developed Countries for the Decade 2011-2020’,Fourth United 
Nations Conference on the Least Developed Countries, District General 11 May 2011, Istanbul, Turkey 9-13 
May 2011,  http://ldc4istanbul.org/uploads/IPoA.pdf, Health and Human Rights Resource Guide,  available 
https://www.hhrguide.org/2017/06/09/access-to-medicines-and-human-rights/#_ftnref10  
13 Ibid 
14 Taylor 2010 
15 Ibid 
16 Ibid 
‘Millennium Declaration’, the ‘Monterrey Consensus of the International Conference on Financing 
for Development’, the ‘Plan of Implementation of the World Summit on Sustainable Development’ 
(Johannesburg Plan of Implementation), the ‘2005 World Summit Outcome’, the ‘Doha Declaration 
on Financing for Development’ and the outcome document of the ‘High-level Plenary Meeting of the 
General Assembly on the Millennium Development Goals’.17  
IP reform  
In order to accede into WTO Sudan will need to implement and develop ‘effective’ laws.18 Sudan has 
joined several organisations, conventions and agreements which are relevant to IP these include:19 
 
- the African Regional Intellectual Property Organization (ARIPO) in 1978; 
- WIPO (1967) in 1974; 
- the Paris Convention (1883) in 1974; 
- the Berne Convention (1886) in 2002; 
- the Madrid Agreement on International Registration of Marks (1891) in 1984; and  
- the Patent Cooperation Treaty (PCT) (1970) in 1984. 20 
 
                                                 
17 UN, ‘Programme of Action for the Least Developed Countries for the Decade 2011-2020’,Fourth United 
Nations Conference on the Least Developed Countries, District General 11 May 2011, Istanbul, Turkey 9-13 
May 2011,  http://ldc4istanbul.org/uploads/IPoA.pdf  
18 Effective legislation has been debated in the ‘context ‘of Article 27.3(b) of the TRIPS Agreement in relation 
to plant varieties. Mosoti, Victor. “The Legal Implications of Sudan's Accession to the World Trade 
Organization.” African Affairs, vol. 103, no. 411, 2004, pp. 269–282. JSTOR, www.jstor.org/stable/3518612. 
19 Samia Satti Osman Mohamed Nour (2015) The economic importance and impacts of intellectual property 
rights (IPRs) in Sudan, African Journal of Science, Technology, Innovation and Development, 7:2, 126-143, 
DOI: 10.1080/20421338.2014.903014 
20 Sudan’s legal framework is encapsulated in the following laws:  
-The Trademarks Law (1931, 1969); 
- Patent Law (1971); 
-Copyright Law (1974); 
- Industrial Designs Law (1974); 
-Civil Procedures Law (1983); 
-Civil Transactions Law (1984); 
- Copyright and Related Rights Law (1996); 
- Criminal Law (1991); 
-Criminal Procedure Law (1991); and  
-Literary and Artistic Works Law (2000). 
 See also Samia Satti Osman Mohamed Nour (2015) The economic importance and impacts of intellectual 
property rights (IPRs) in Sudan, African Journal of Science, Technology, Innovation and Development, 7:2, 
126-143, DOI: 10.1080/20421338.2014.903014 
Sudan is also a member of the African Regional Intellectual Property Organization21 (ARIPO).22 This 
organisation includes a Harare Protocol;23which is relevant to patents. ARIPO aims to harmonise 
patent laws with the members national laws.24  
 
Sudan has Patent Regulations of 1981 which are linked to  its Patent Law No.58 of 1971.25 A closer 
look at Sudan’s Patent Law No.58 of 1971 reveals the following:  
 
- Sudan’s patentability criteria includes: any invention which is new, involves an inventive step 
and is capable of industrial application.26However Sudan’s patent law also stipulates that ‘any 
invention constituting an improvement’ on the patented invention is also patentable ‘ if it is 
new, involves an inventive step and is capable of industrial application'27. This definition is 
too wide and could result in an ever greening loophole that pharmaceutical companies may 
exploit. 
- Section 18 on granting a patent ‘as to without Examination as to the Substance of the 
Application’ is confusing because it states that the tests for patentability, listed in the previous 
sections of the 1971 Act, will not apply if: the terms of application in section 12 are 
observed28, there is a unity of the invention as per section 1429, fees are paid as per section 
                                                 
21 South Sudan, however is not part of ARIPO, but it may create its own set of laws, Will south Sudan get its IP 
right? 2012. Managing Intellectual Property (03), 
https://search.proquest.com/docview/994905624?accountid=17233 , last accessed August 6, 2018. 
22 This organisation has four protocols to which Sudan is a party to two; the Lusaka Agreement which Sudan 
signed on 2 May 1978, and the Harare Protocol which Sudan signed on 25 April 1984.  ARIPO Annual Report 
2016, ARIPO Harare, Zimbabwe 2017, available on http://www.aripo.org/publications/annual-reports/item/199-
aripo-annual-report-2016 , last accessed on 6 August 2018. (Hereafter ARIPO Report 2016) 
23 ARIPO Report 2016 
24ARIPO Report 2016. 
25 Patent Regulation 1981 available at WIPO, https://wipolex.wipo.int/en/legislation/details/15035 
26 Section 3.1 Chapter two, Sudan Patent Law No.58 1971 
27 Section 3.2 Chapter two, Sudan Patent Law No.58 1971 
28 Section 12 states: Terms of Applications: 
(1) An application for a patent shall be made to the Patent Application Office and shall contain: 
(a) the complete name and address of the applicant and, if the applicant’s address is outside tne Democratic 
Republic of the Sudan, the indication of an address for service within the Democratic Republic of the Sudan; 
(b) a description of the invention with the drawings, if any, referred to therein; 
(c) one or more claims. 
(2) Where appropriate, the application for the patent shall be accompanied by a declaration, signed by the true 
inventor, requesting that he be mentioned as such in the patent and giving his name and address. 
(3) Where the application is made by an agent, it shall be accompanied by a signed power of attorney; 
authentication or certification of the signature shall not be necessary. 
(4) The details of the formal requirements with which an application for a patent must comply shall be 
prescribed in the Regulations. 
 
29 Section 14 states:  Unity of the Invention: 
(1) An application for a patent shall relate to one invention only. 
(2) Subject to the preceding subsection, an application for a patent may include, in particular: 
(a) apart from claims for one or more products, claims for one or more  manufacturing processes for the product 
or products, and claims for one or more applications of the product or products; 
1630, and examination that these have been complied with as per section 17.31 This is 
confusing because these sections outline the filing process which will always mean that the 
patentability criteria could be side-stepped. 
- Furthermore  an inventive step has been defined as a process which ‘does not obviously 
follow…either as to the method or as to the industrial results it produces’32 which means 
patenting, technically, should not include new uses for old chemical entities.  However 
section 14.2(a) and (b) contradict this by stating that ‘claims for one or more 
manufacturing processes for the product or products, and claims for one or more applications 
of the product or products’ and ‘claims for means of working the process or processes, claims 
for the product or products which result from that working, and claims for the application of 
such products’ are patentable.  
- It is not clear what the scope of protection includes under section 22 of the Act.33 
- It is interesting to note the prior manufacturing section which states that if a products has been 
manufactured or made preparations to manufacture or use, in good faith, it should continue to 
be manufactured even when a patent has been granted.34  
                                                 
(b) apart from claims for one or more manufacturing processes, claims for means of working the process or 
processes, claims for the product or products which result from that working, and claims for the application of 
such products. 
 
30 Section 16 states: Payment of Fees: An application for a patent shall not be accepted unless the fee prescribed 
for this effect has been paid. 
31 Section 17 states: Examination of Application as to Form: 
(1) The Patent Office shall examine the application as to its conformity 
with Sections 12, 14, 15 and 16. 
(2) Where the provisions of Sections 12 or 16 have not been complied 
with, a patent shall not be granted; where the provisions of Section 15 
have not been complied with, the Patent Office shall not mention in the 
patent the priority claimed. 
(3) Where the application does not fulfill the requirements of Section 14, 
the applicant shall be invited by the Patent Office to restrict the 
application so that it relates to only one invention. At the same time, the 
Patent Office shall notify the applicant that, within a period of three 
months, he may file, for the rest of the application, one or more divisional 
applications, which shall benefit from the date of the filing of the original 
application, and, if relevant, from the priority date claimed under Section 
15. Where the applicant does not comply with this invitation to restrict the 
original application to one invention, no patent shall be granted. 
32 Section 5 Chapter two, Sudan Patent Law No.58 1971 
33 Section 22 states: Scope of Protection: 
(1) The scope of the protection conferred by the patent shall be 
determined by the terms of the claims. 
(2) The description and the drawings included in the patent shall be used 
to interpret the claims. 
34 Section 24 states: Rights Derived from Prior Manufacture Use: 
Any person who, at the date of the filing of the patent application by 
another person, or at the date of priority claimed in respect of such validly 
application, was, in good faith, manufacturing the product or applying the 
process, which is the subject of the invention, or had made serious 
preparations with a view to such manufacture or use, shall, despite the 
- Section 25.1 states that a duration of a patent is 20 years from the date of filing.35 
- Chapter 9 is concerned with compulsory licensing and lists ‘non-working and similar 
conditions’ where importation, interestingly, is not considered as working a patent36. A 
compulsory license is granted ‘for Products and Processes Declared to be of Vital Importance 
for the Defense or Economy of the Country or for Public Health’37 and on the basis of ‘inter-
dependence of patents’.38 
Reading Sudan’s Patent Law No.58 of 1971 has been difficult because of the many typographical 
errors and redundancies that exist within the text. 39 A thorough examination of the language is 
necessary to ensure clarity in this legislation so that the government and interested parties could 




There is a suggestion that Sudan should make allies of countries that have acceded into the WTO as 
this will mean less pressure in the Working Party bilateral and multilateral negotiations.40However 
bilateral negotiations are inevitable before such accessions for example Cambodia’s accession was 
delayed because it was based of its bilateral negotiations with the EU.41 
 
Sudan should also adopt a similar approach to the Tokyo Round’s ‘a la carte pluri-lateral approach’ 
where members were at liberty to choose which ‘codes’ to apply.42 The single undertaking approach 
is preferred by multilaterals as it encourages the ‘unconditional most favoured nation obligation’ 
which the ‘a la carte’ approach threatens.43 A ‘pick and mix’ approach for Sudan means that it will be 
able to benefit from the tools provided by the WTO to improve its economy and access to medicine. 
                                                 
patent, have the right to continue such acts 
and, with respect to products obtained thereby, to perform the other acts 
referred to in section 21. This right is only transferable with the 
undertaking which is the 
beneficiary of the right. 
35 Patent Law No. 58 of 1971 
36 S.34.2 states : ‘ …importation shall not constitute a legitimate reason’  
37 S.35 Patent Law No. 58 of 1971 
38 S. 36 Patent Law No. 58 of 1971 
39 For example s.35 states: ‘The Minister may, by order, provide that, for certain patented products or processes, 
or for certain categories of such products amd processes, which are declared by that order of vital importance 
for the defense or the economy of the Democratic Republic of the Sudan or for public health, compulsory 
licenses may be granted, in the conditions provided for in Section 34, evem before the expiration of the period 
mentioned in subsection (1) of that Section and even for importation into the Democratic Republic of the 
Sudan.’ 
40 Mosoti, Victor. “The Legal Implications of Sudan's Accession to the World Trade Organization.” African 
Affairs, vol. 103, no. 411, 2004, pp. 269–282. JSTOR, JSTOR, www.jstor.org/stable/3518612. 
41 Ibid 
42 Kennedy 2006 
43 Kennedy 2006 
However, an approach that will review the existing laws and establish which ones are beneficial to 
Sudan through the expertise of an international organization such as the WTO will be expensive for 
Sudan;44especially that an implementation structure is necessary to follow such recommendations. 45  
Technical assistance by developing countries is required by Article 67 of TRIPS and reiterated in 
2005 TRIPS Council decision46. To assess the effectiveness of technical assistance the TRIPS Council 
has requested that developed countries produce annual activity reports of their assistance to 
LDCs.47Communication from the Delegation of Zambia shows that although some assistance has been 
provided it has not been the right or adequate amount of assistance 48. The Sudanese Minister of Trade 
re-affirmed this by stating that they have received some assistance, in the form of donations in 
$100,000 to support Sudan’s accession and a re-affirmation of support from China under its ‘WTO’s 
Least-Developed Countries and Accessions Programme’49  from WTO members, however, they 
require more technical assistance to help them with their accession.50 It is not only the case of 
affordable medicine but the availability of medicine which is the issue in Sudan.51 This means that 
Sudan  has not been receiving enough technical assistance to help access to medicine.   
 
 
Attracting Foreign Direct Investment (FDI) before acceding into TRIPS 
As well as making allies of WTO members Sudan should attempt to re-build its relationship with the 
outside world and attract FDIs, especially that the US sanctions have been lifted, and because Sudan 
                                                 
44 Walden Bello, Multilateral Punishment: The Philippines in the WTO, 199, Mosoti, Victor. “The Legal 
Implications of Sudan's Accession to the World Trade Organization.” African Affairs, vol. 103, no. 411, 2004, 
pp. 269–282. JSTOR, JSTOR, www.jstor.org/stable/3518612. 
45 Walden Bello, Multilateral Punishment: The Philippines in the WTO, 199, Mosoti, Victor. “The Legal 
Implications of Sudan's Accession to the World Trade Organization.” African Affairs, vol. 103, no. 411, 2004, 
pp. 269–282. JSTOR, www.jstor.org/stable/3518612.  
46 K. Kennedy, e2005 TRIPS Extension for the Least-Developed Countries: A Failure of the Single Undertaking 
Approach?, 40 Int'l Law. 683 (2006). (Hereafter Kennedy 2006) 
47 Council for Trade-Related Aspects of Intellectual Property Rights, Decision of the Council for TRIPS of 19 
February 2003, Implementation of Article 66.2 of the TRIPS Agreement, IP/c/28 (Feb. 20, 2003). Kennedy 
2006 
48 Kennedy 2006 ,CommunicationfromtheDelegationofZambiaonbehalfoftheLeast-DevelopedCountryMembers, 
Request for an Extension of the Transitional Period under Article 66.1 of the TRIPS Agreement, IP/c/w/457  
(Oct. 21, 2005) 
49 WTO, ‘Sudan resumes WTO membership negotiations’, 31 January 2017, available on 
https://www.wto.org/english/news_e/news17_e/acc_sdn_31jan17_e.htm  
50 WTO, ‘Positive momentum for Sudan’s WTO membership negotiations’ , 14 July 2017  available on 
https://www.wto.org/english/news_e/news17_e/acc_sdn_17jul17_e.htm 
51 World Health Organization EMRO, ‘Access to key medicine for nearly 2 million Sudanese due to USAID 
contribution’,  available on http://www.emro.who.int/sdn/sudan-infocus/access-to-key-medicine.html , accessed 
on 28 November 2017 
and South Sudan have signed a peace agreement in September 2018 ending their civil war which 
started in 2013.52 Building relationships , however, may be difficult ,especially that Sudan has the 
‘the fifth-worst ranking in Transparency International’s global Corruption Perceptions Index.’ 53 
Therefore ‘attracting investors, analysts say, needs changes in everything from business regulations to 
education, as well as investment in roads, rail and ports.’ 54 However, Uganda, Rwanda and Cambodia 
were able to benefit from their ties with the developing world. 55 Sudan could attempt to benefit from 
its relationship with China as one of its biggest investors56.  
There has been a lot of debate on whether strong IP attracts FDI and the correlation between increased 
IPRS and increased flow FDI is a contested issue. Increased IPRS means that imitation is reduced by 
national companies and supports multinational companies which arguably also hinder FDI flows as 
they form market monopolies that discourages investments.57The benefits of trade between the Jordan 
and the US are yet to be realised. Indeed, Jordan’s production still lags behind developed 
countries58.This could be because Jordan has small industries hence penetrating the US market is 
hard. Critics of globalisation, however, have disapproved of FTAs as a myth circulated by developed 
countries to pre-emptively gain access to developing country markets and retort that FTAs should 
result in fair trade instead.59   
An International Intellectual Property Institute Report (IIPI) of 2004 claims that Jordan’s economy 
has benefitted from increased IPR protection between 1998 and 2001 in that health-service 
                                                 
52 Jason Burke and Benjamin Takpiny, ‘South Sudan celebrates new peace accord amid joy – and scepticism’, 
The guardian, 31 October 2018, available on https://www.theguardian.com/global-
development/2018/oct/31/south-sudan-celebrates-new-peace-accord-amid-joy-and-scepticism , last accessed on 
20 December 2018 
53 S. Gebre  and O. Francis, ‘Revival Beckons for Sudan as U.S. Lifts Economic Sanctions’, January 30, 2017. 
(Hereafter Gebre and Francis) 
54 Gebre and Francis 
55 E. Bonadio, ‘Should the world’s poorest countries be allowed to continue copying patent-protected drugs?’, 
24th November, 2015, CITY University of London, https://www.city.ac.uk/news/2015/november/should-the-
worlds-poorest-countries-be-allowed-to-continue-copying-patent-protected-drugs (Hereaftr Bonadio 2015) 
56 See Statement by H.E. Mr Badr Eldin Suleiman 
Advisor, Presidency of the Republic and National Chief Negotiator for the Accession of Sudan to the WTO 
congratulating China in 2001 on its WTO accession and calling it a ‘historic accession  not merely because of 
China's size or weight in global trade but essentially for greater symbolic and actual status of the People's 
Republic of China in the midst of the developing nations and its unique contributions to the world's civilization’ 
see also Joseph Hammond, Sudan: China's Original Foothold in Africa, June 14, 2017 
https://thediplomat.com/2017/06/sudan-chinas-original-foothold-in-africa/ 
57 Zhang H & Yang, X ‘Trade-related aspects of intellectual property rights agreements and the upsurge in 
foreign direct investment in developing countries’, Economic Analysis and Policy, Volume 50, June 01, 2016, 
Pages 91-99 
58  Sara Elizabeth William, ‘ANALYSIS: Jordan struggles to keep economic fires burning’ , Middle East Eye 28 
September 2016, available on http://www.middleeasteye.net/news/analysis-lights-are-about-go-out-jordan-s-
long-suffering-economy-2060454736  
59 Joseph Stiglitz, Globalization and Its Discontents, (New York: W.W. Norton, 2002); Ha-Joon  
Chang, Bad Samaritans: Rich Nations, Poor Policies and the Threat to the Developing World, (London: 
Random  House, 2007) and ―Rigged Rules and Double Standards: Trade, Globalization, and the Fight Against 
Poverty,‖ Oxfam International, 2002. http://www.maketradefair.com/en/ 
contributions to the Jordanian gross domestic product grew from 2.8% in 1997 to 3.5% in 2001, and 
health-services employment grew 52% since 1997.60 The report further stated that pharmaceutical 
exports from Jordan expanded 30 percent from 1999 to 2002.61This economic growth was attributed 
to Jordan’s increased patent protection. 62 This report however, was found to be ‘exaggerated and the 
costs under-estimated’63.  
 
There is no evidence to support claims that the FTAs in Jordan have ‘enhanced availability and 
accessibility of medicines in Jordan, attracted foreign investment, improved R&D capacity of local 
manufacturers or led to more collaboration between national and multinational pharmaceutical 
companies.’64 Another study of the FTA in 2007 by Oxfam65reported that medicines prices ‘have 
increased significantly’ and predicts that medicine prices will continue to rise and that the TRIPS 
flexibilities will not be used to reduce the costs of medicines. 66 The most recent study on the effect of 
TRIPS plus on Jordan’s medicine reaffirms that there is undoubtedly a significant increase in prices of 
medication.67 
 
                                                 
60 Ryan MP and Shanebrook J. Establishing globally competitive pharmaceutical and bio-medical technology 
industries in Jordan: assessment of business strategies and the enabling envir- onment. Online, 
http://pdf.usaid.gov/pdf_docs/PNADA539.pdf, Ryan B Abbott, Rania Bader, Lina Bajjali, Taher Abu ElSamen, 
Thamer Obeidat, Hanan Sboul, Mustafa Shwayat and Ibrahim Alabbadi ‘The price of medicines in Jordan: the 
cost of trade-based intellectual property’, Journal of Generic Medicines  
Vol 9, Issue 2, pp. 75 – 85, May-24-2012, 10.1177/1741134312447499, can be accessed on 
http://journals.sagepub.com/doi/pdf/10.1177/1741134312447499  
61 R. Abbott, ‘Inside Views: Access to Medicines And Intellectual Property in Jordan’, Intellectual Property 
Watch, 23/07/2012 can be accessed on https://www.ip-watch.org/2012/07/23/access-to-medicines-and-
intellectual-property-in-jordan/, See Michael P. Ryan and Jillian Shanebrook, Establishing Globally 
Competitive Pharmaceutical and Bio-medical Technology Industries in Jordan: Assessment of Business 
Strategies and the Enabling Environment, International Intellectual Property Institute, Washington DC and 
Achievement of Market-Friendly Initiatives and Results Programme (AMIR), Jordan , August 2004 
62 Ryan MP and Shanebrook J. Establishing globally competitive pharmaceutical and bio-medical technology 
industries in Jordan: assessment of business strategies and the enabling envir- onment. Online, 
http://pdf.usaid.gov/pdf_docs/PNADA539.pdf, Ryan B Abbott, Rania Bader, Lina Bajjali, Taher Abu ElSamen, 
Thamer Obeidat, Hanan Sboul, Mustafa Shwayat and Ibrahim Alabbadi ‘The price of medicines in Jordan: the 
cost of trade-based intellectual property’, Journal of Generic Medicines  
Vol 9, Issue 2, pp. 75 – 85, May-24-2012, 10.1177/1741134312447499, can be accessed on 
http://journals.sagepub.com/doi/pdf/10.1177/1741134312447499  
63 El-Said H and El-Said M. TRIPS-plus implications for access to medicines in developing countries: lessons 
from Jordan– United States free trade agreement. J World Intellect Property 2007; 10(6): 438–475. 
64 R. Abbott, ‘Inside Views: Access to Medicines And Intellectual Property in Jordan’, Intellectual Property 
Watch, 23/07/2012 can be accessed on https://www.ip-watch.org/2012/07/23/access-to-medicines-and-
intellectual-property-in-jordan/ 
65 Malpani 2007 
66 Malpani 2007 
67 Ryan B Abbott, Rania Bader, Lina Bajjali, Taher Abu ElSamen, Thamer Obeidat, Hanan Sboul, Mustafa 
Shwayat and Ibrahim Alabbadi ‘The price of medicines in Jordan: the cost of trade-based intellectual property’, 
Journal of Generic Medicines, Vol 9, Issue 2, pp. 75 – 85, May-24-2012, 10.1177/1741134312447499, can be 
accessed on http://journals.sagepub.com/doi/pdf/10.1177/1741134312447499 
Jordan’s FDIs pre-TRIPS, pre Jordan US FTA (JUSFTA) and pre Jordan EU Associate Agreement 
(JEUAA) were stronger and were on the rise in1997 due to privatisation.68 The fact that stronger IPRS 
have not attracted any significant FDIs in Jordan not only affects Jordan’s access to medicine nor does 
it help Jordan’s economy. An explanation for this could be the increased unrest in the region as 
mentioned above due to the Persian War of 1991. This is an important factor to consider Jordan’s 
continuous political unrest undoubtedly has affected its trade profile and economy.  This is re-
affirmed by a WTO report which stated that FDI inflows have decreased between 2008 to 2012 due to 
the global financial crisis, however despite the fact that inflows have improved since then they 
continue to ‘mainly due to concerns about the due to political instability and conflict in the region.’69 
More specifically according to Santander’s Trade Portal Jordan’s FDI ‘skyrocketed’ until 200670 but 
then has arguable declined because of economic crisis,  
 
The above means that FTAs in Jordan have reaped little or no benefit with respect to attracting FDI 
because of increased IPRS. This disproves the US’s prediction that the JUSFTA will result in great 
trade expansion for Jordan. 71 This prediction, along with special 301 report discussed previously, 
could be another form of pressure on Jordan to agree to the terms set out by the US in the FTA and 
agree to sign other FTAs. ‘Predictions’ or promises by the US have not been the only pressure exerted 
on Jordan to agree the terms of the JUSFTA. Threat of trade sanctions may have been another form of 
pressure used by the US. For example, The Department of Commerce’s Market Access and 
Compliance offices monitor JUSFTA to ensure that Jordan fully complies with its trade obligations.72  
It could be argued that there has not been an increase in FDIs due to Jordan’s unstable economy in 
dealing with crisis and especially the Syrian crisis.73 
                                                 
68 Council for Trade-Related Aspects of Intellectual Property Rights, TRIPS and Public Health: Submission by 
the African Group et al., at 3-4, IP/C/W/296 (June 29, 2001) (describing Resolution 200/33 adopted by the 57th 
Session of the U.N. Commission on Human Rights, which called upon its members to take 
measures to safeguard access to preventative, curative, or palliative pharmaceuticals); Council for Trade-Related 
Aspects of Intellectual Property Rights, Ministerial Declaration on the TRIPS Agreement and Public Health: 
Submission by the African Group et al., IP/C/W/312 (Oct. 4, 2001) 
69 WTO, Trade Policy Review report by the Secretariat, WT/TPR/S/325, 13 October 2015, available on 
https://docs.wto.org/dol2fe/Pages/FE_Search/FE_S_S006.aspx?Query=(%20@Symbol=%20wt/tpr*%20or%20
press/tprb/*%20)%20and%20(%20@Title=%20bahrain%20)&Language=ENGLISH&Context=FomerScripted
Search&languageUIChanged=true#    
70 JORDAN: FOREIGN INVESTMENT: FDI in Figures, Santander Trade Portal, available on   
https://en.portal.santandertrade.com/establish-overseas/jordan/investing  
71 Charles T. Collins-Chase, Comment, The Case Against TRIPS-Plus 
Protection in Developing Countries Facing AIDS Epidemics, 29 U. PA. J. INT’L L. 763, 
766–69 (2008) .793 available at 
https://www.law.upenn.edu/journals/jil/articles/volume29/issue3/CollinsChase29U.Pa.J.Int'lL.763(2008).pdf 
accessed on 30 March 2016 
72 http://www.export.gov/fta/jordan/ 
73 European Commission,Report on Implementation of 
EU Free Trade Agreements 1 January 2017 - 31 December 2017, 2018, available on   
http://trade.ec.europa.eu/doclib/docs/2018/october/tradoc_157468.pdf , last accessed on 3 December 2018 
The reported FDIs into Jordan, since the signing of JUSFTA, has been by foreign drug companies 
which expanded their scientific offices, and used aggressive sales tactics to ensure that expensive 
patented medicines are used in lieu of inexpensive generics. 74 This strengthening of the drug 
companies position has not been favourable and it was foreseen by the Jordanian Industrial 
Development Bank (“IDB”), which  published a study  in 1995 that found strengthened IPRS would 
harm local production, in terms of both investment and output; decrease local production, and thus 
employment levels; increase drug imports and decrease exports; and increase pharmaceutical prices.75  
Jordan has not reaped any real benefits since signing the FTA with US as domestic innovation was 
not encouraged and there has not been an increase in additional FDI in pharmaceutical manufacturing 
or R&D.76 Signing FTAs, however, has not stopped Jordan from taking international initiatives to 
endorse generic competition which includes ‘restricting data protection to a narrow definition of 
‘new’ uses and limiting applications for data protection to a short period following market approval in 
the originator country.’77 
In comparison with Jordan Bahrain, an essentially crisis free country, pre-TRIPS attracted ‘very little’ 
FDIs from outside the GCC region.78  Bahrain still has FDI restrictions in which a number of 
businesses are reserved for Bahraini nationals and GCC nationals79; however, they are ‘healthy and 
growing’80.  Bahrain has been increasing its efforts to diversify from its oil and gas, however it still 
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needs to attract more FDI to ‘accelerate Bahrain’s economic diversification efforts’.81 Further 
attempts to implement steps to attract FDI  in Bahrain were futile as Bahrain’s FDI rate dropped 
sharply in 2015 (-4.5%) after reaching stable growth rates between 2.7% and 3% since 2011. 82 
Egypt, for example, used compulsory licensing as a tool before fully implementing TRIPS and the 
Doha Declaration to issue a compulsory license for a generic form of Viagra two months after Pfizer’s 
patented Viagra entered into the market which resulted in a decrease of FDI from $948 million in 
198783to $509.4 million in 2001- 02.84 FDIs have increased since, however, these increases have been 
predominantly petroleum based investments 85. Moreover Pharmaceutical companies ‘have 
deliberately avoided’86 investing in Egypt, a country ‘which relies heavily on FDI’ as a result.87 
Egypt’s issuance of a compulsory license, for the generic form of Viagra, would have been allowed 
under the Doha Declaration88. If Egypt was subject to stricter IPRS then the use of a compulsory 
license would have been limited to a national emergency which does not seem to be the case. If Egypt 
was subject to stricter IPRS then, arguably, it would not have missed out on an increase of FDIs. 
Unsurprisingly extensive compulsory licensing in Egypt has reportedly led to a decrease of FDI from 
$948 million in 1987 to $509.4 million in 2001–02.89  
Thailand is another country which suffered a decrease of FDI as a result of its lax approach towards 
compulsory licensing as permitted by the Doha Declaration. 90 For example announcing using a 
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compulsory license for ARV efvarinez in 200691  and considering breaking patents in non-life 
threatening conditions92  resulted in private investment falling ‘dramatically between 2005 and 
2007’93 and ‘gross private investment growth fell from 10.6% to .5% in 2007, its lowest since 2000.’94 
Furthermore as a result of using compulsory licenses  FDIs in Thailand has ‘transferred amazingly 
little tacit knowledge and technology, as only a handful of companies have set up research 
establishments in Thailand.’95 This failure , undoubtedly, has been because the US has downgraded 
Thailand in its special 301 report from being on the ‘Watch List’ to being on the ‘Priority Watch 
List’.96  
 FDI is about attracting the right type of investment97 to diversify the economy. 98 There is an 
argument which suggests that ‘countries with weaker protection can become more attractive as they 
strengthen their IPRs, and the relative attractiveness of those with strong IPRs already in existence 
can fall’99.  
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Hassan, Emmanuel, Ohid Yaqub and Stephanie Diepeveen. Intellectual Property and Developing Countries: A 
review of the literature. Santa Monica, CA: RAND Corporation, 2010. 
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In addition, FDI in stricter IP countries are more relevant to high technology industries100.  Licensing 
is encouraged when there is a strong IPRS.101 This means that firms choose FDI ‘over licensing when 
protection is weak, as firms are more able to maintain direct control over their proprietary assets 
through internalised foreign production or in- house foreign R&D.’102 This means that stronger IPRS 
‘diminishes the incentive for FDI at the margin for R&D-intensive industries’.103 
 
As a result Sudan should attempt to attract as much FDI as possible before acceding into WTO. It 
may be difficult, for Sudan , however, to attract FDIs unless Sudan teams up with a capital holder. It 
is difficult for Sudan to attract FDIs because it operates outside the scope of the WTO with a lack of 
IP rights.    Uganda for example has teamed up with CIPLA to manufacture and produce triple –
combination antiretroviral drugs.104 Uganda’s FDI flow has been on the increase and it is ‘one of the 
countries that attracts the most FDI in East Africa’.105 Being a manufacturer of generics, however, 
does not guarantee FDI flow; for example Rwanda has not been able to attract a constant flow of FDI 
due to various factors such as ‘low human resource capacity, poor infrastructure, landlocked position, 
high operating costs, limited natural resources and the political instability’.106 Sudan could start by 
approaching capital holders such as CIPLA to follow in Uganda’s approach in attracting FDI. 
 
Arguably Sudan will attract more FDI once it has acceded into WTO. In theory,  if TRIPS is 
implemented then FDIs will allegedly be attracted which will improve the economy of Sudan. 
However, there are three issues with this, firstly that the economies of LDCs, such as Sudan, are 
lacking in any event and ‘without the fundamentals firmly in place-political stability, desirable 
geographic lo- cation, adequate infrastructure, human capacity, functioning legal institutions, 
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enforceable contract rights, open trade policies, and intellectual property protection-a country will not 
be an attractive host site for FDI’ 107 and subsequently implementing TRIPS is not possible at this 
stage. Secondly lessons from Jordan and Bahrain show that implementing TRIPS does not necessarily 
attract FDIs and thirdly even if FDI is attracted there is no menu to choose from the right amount of 
FDI that Sudan will attract.  
It is argued that there are many benefits to Sudan from acceding into WTO such as: trade facilitation, 
development of pro-growth trade policies and profiting from a dispute settlement mechanism108. 
Disadvantages to Sudan could be a draining of resources in the lengthy and costly process of 
accession, political opposition to accession.  
Additionally, Sudan is not likely to attract much FDI especially when the US has previously placed 
economic sanctions against Sudan declaring it as a state sponsor for terrorism.109Attracting investment 
could also be difficult because of Sudan’s ‘negative picture’110which has led to its ‘international 
isolation’. 111 Likewise, acceding into TRIPS is not an end-all game for Sudan but could be the 
beginning of a chain of bilateral agreements and TRIPS plus conditions as evidenced by Jordan and 
Bahrain which will restrict Sudan’s access to medicine.  
Further negatives to Sudan will include increased commitments that other recently acceded LDCs 
have undergone ‘For example, while original LDC members have undertaken commitments on 20 
services subsectors, on average - out of the 160 subsectors identified by the WTO classification list - 
Cambodia, Nepal, and Cape Verde undertook commitments in 94, 99 and 77 of their service 
subsectors, respectively.’112 A newly acceded LDC does not necessarily have the capacity to deal with 
the bureaucracy and commitments imposed by the WTO.  
 
 
 Manufacturing generics 
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As mentioned above Sudan is an LDC and LDCs have until 2033 to comply with TRIPS. This is one 
area of strength which Sudan could benefit from. Sudan could become a manufacturer of generics. 
The LDC’s market is a huge market comprising of 900m and is a market which suffers a much higher 
‘disease burden’113. This means that the demand for medication is constant. 114 it will be interesting to 
note the effect of the India-EU on India’s access to medicine. 115 Countries such as Uganda, Cambodia 
and Rwanda have also taken advantage of the WTO’s 2033 extension by developing their own 
pharmaceutical industries.  
 
Sudan should learn from Rwanda’s difficulties in being a manufacturer. Rwanda’s struggles to 
become a robust manufacturer of generics because of various issues such as: ‘underdeveloped 
regulatory framework coupled with inadequate regulatory capacity, a lack of harmonization between 
industrial and health policies, a cumbersome and unclear procurement process for key inputs, the 
necessity of importing raw materials or active pharmaceutical ingredients (APIs), and high water and 
energy costs, that increase the overall cost of production.’116 
A private sector brief by USAID has identified that the majority of African countries have a 
‘pharmaceutical manufacturing capability’117 and identified that an LDC could develop a ‘homegrown 
pharmaceutical sector’ through various means such as:  
-Phased development: this means that Sudan should start slowly by basic production before 
progressing into more complex drugs. 118 Sudan has twenty four registered pharmaceutical 
manufacturers119 which produce ‘generic medicines in oral and topical pharmaceutical dosage 
form’120, however local production only presents 5% of the Sudanese population’s needs of essential 
medicines 121.  This means that Sudan should perhaps increase or diversify its pharmaceutical 
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manufacturer capacities especially with Malaria identified as the number one cause of being admitted 
into hospital. 
- Multinationals involvement:  Sudan could team up with a multinational and many multinational 
pharmaceuticals have seized the opportunity to partner up with local entities in an LDC to spur 
production in countries as diverse as South Africa, Nigeria, Kenya, Zimbabwe, Tanzania, Botswana, 
Uganda, Ethiopia and Ghana.122 123 
- Specialisation: South Africa and Ghana to produce Active Pharmaceutical Ingredients which require 
high quality standards. Most African countries have also specialised in ‘producing generic medicines 
and importing APIs and excipients, primarily from India and China.’124 Sudan could utilise its 
speciality acquired across its fourteen pharmaceutical manufacturers to  
-Supportive policies: alignment of various policies such as investment policies will have an impact on 
strengthening Sudan’s pharmaceutical capability 125 
- Joint ventures:  A joint venture could be beneficial to Sudan as it will mean that skills and 
technology could be learned and transferred. Many countries such as Kenya, Tanzania and Ethiopia 
has reaped benefits from joint partnerships which have become wholly locally owned private firms.126  
Improving Standards 
It has been recommended by a recent study that the availability of medicine in Sudan may be 
improved with by a ‘Central Medicines Supplies (CMS) which is a governmental corporation; among 
its responsibilities is to ensure quality medicines and other medical supplies are available with 
affordable prices.’ 127 CMS will be able to enhance access to medicine through an ‘implementation of 
good procurement practice, good storage practice and good distribution and transportation practices’. 
128  This could be achieved through creating a government assisted RDF (Revolving Drug Fund) 
which will ‘be responsible for drug supply management system at the state level.’ 129  
Safeguarding public health by guaranteeing that pharmaceuticals and medicines meet appropriate 
‘standards of safety, quality and efficacy’ is a the primary objective of state and federal departments 
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of pharmacy. 130  The Pharmacy and Poisons Act and the Federal General Directorate of Pharmacy 
(FGDOP) are the tools which Sudan uses to ensure that these objectives are achieved. 131 This is 
important because there have been issues over the quality of medicine in Sudan.132 
Training pharmacists in Sudan is also recommended because ‘there are many pharmacies working 
without qualified pharmacists.’ 133 Furthermore an effort, by FDGOP, into ensuring that medicines 
‘are registered and they came from legal sources’134is crucial to Sudan’s public’s access to medicine.  
The CMSPO should also stop encourage and importing manufacturing and registering unregistered 
medicines135   and selling tender’s products to private pharmacies because it ‘  
it makes inspectors task too difficult (that is, cannot identify the source of medicine whether it is 
CMSPO or not).” 136 
Form an advisory committee 
Sudan needs to form an advisory committee to advise on negotiating and acceding to agreements 
which may impact public health. This is a very important lesson because both Bahrain and Jordan 
have not had the benefit of an advisory committee before entering into FTAs. The benefit an advisory 
committee will provide is negotiating favourable terms for Sudan when entering into any agreement 
which will impact its access to health.   
It is inevitable that the Sudanese government will sign more international agreements to appease to 
the international arena.  Sudan has already signed a trade agreement with the US Trade and 
Investment Framework Agreement (TIFA) in 2001137. Sudan has also entered into thirty three 
Bilateral Investment Agreements  (BITs) with various countries;138. An advisory committee would 
have been able to advise on the signing of such agreements.     
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Furthermore Sudan should also benefit from a the Regional Dialogue platform created in 2017 which 
was established for countries to discuss issues that they have struggled with when acceding into 
WTO.  This platform, whilst only annual, will be invaluable for Sudan on its accession journey into 
WTO membership.139 The experience that other countries 
 
Conclusion 
Sudan should focus on the most limiting factor which constrains its access to medicine. Sudan has the 
benefit of learning from developing countries as well least developing countries to develop its 
manufacturing capabilities and further assist the country’s healthcare needs. Sudan is unlikely to 
attract FDIs once it acceded into the WTO/TRIPS with its history and especially that it has been 
singled out by the US as a terrorist state. Furthermore, it has not been proven that strengthened IPRS 
attracts FDI. Sudan is struggling with poverty could it afford to a) implement TRIPS b) pay for high 
price medications c) go through the bureaucracy of applying compulsory licenses. The issue is not 
that TRIPS will make access to medicine expensive but that it will also hinder Sudan from 
progressing economically as it will attract more bilateral agreements from other countries and 
especially the US with its new approach. 
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